This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2007 Sep 29;370(9593):1103-4.

doi: 10.1016/S0140-6736(07)61488-3.

Thiazolidinediones, deadly sins, surrogates, and elephants

John G F Cleland¹, Stephen L Atkin

Affiliations

PMID: 17905146
DOI: 10.1016/S0140-6736(07)61488-3

Comment

Thiazolidinediones, deadly sins, surrogates, and elephants

John G F Cleland et al. Lancet. 2007.

. 2007 Sep 29;370(9593):1103-4.

doi: 10.1016/S0140-6736(07)61488-3.

Authors

John G F Cleland¹, Stephen L Atkin

Affiliation

¹ Department of Cardiology, Castle Hill Hospital, University of Hull, Hull HU16 5JQ, UK. j.g.cleland@hull.ac.uk

PMID: 17905146
DOI: 10.1016/S0140-6736(07)61488-3

No abstract available

PubMed Disclaimer

Comment in

Value of glycaemic control in diabetes.
Bailey CJ, Barnett AH, Petrie JR. Bailey CJ, et al. Lancet. 2008 Jan 12;371(9607):116. doi: 10.1016/S0140-6736(08)60101-4. Lancet. 2008. PMID: 18191682 No abstract available.

Comment on

Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.
Lago RM, Singh PP, Nesto RW. Lago RM, et al. Lancet. 2007 Sep 29;370(9593):1129-36. doi: 10.1016/S0140-6736(07)61514-1. Lancet. 2007. PMID: 17905165 Review.

Similar articles

[Uncertainly after publications on glitazones. Elevated myocardial infarction risk is not a class effect].
Erdmann E, Scherbaum WA. Erdmann E, et al. MMW Fortschr Med. 2007 Dec 6;149(49-50):49-50. doi: 10.1007/BF03365260. MMW Fortschr Med. 2007. PMID: 18236983 German. No abstract available.
Rosiglitazone and cardiovascular disease: a cardiologist's perspective.
Marx N. Marx N. Diab Vasc Dis Res. 2007 Jun;4(2):80-1. doi: 10.3132/dvdr.2007.023. Diab Vasc Dis Res. 2007. PMID: 17654439 No abstract available.
The rosigliazone meta-analysis: lessons for the future.
Shuster JJ, Schatz DA. Shuster JJ, et al. Diabetes Care. 2008 Mar;31(3):e10. doi: 10.2337/dc07-2147. Diabetes Care. 2008. PMID: 18308673 No abstract available.
The rosiglitazone meta-analysis.
McCullough PA, Lepor NE. McCullough PA, et al. Rev Cardiovasc Med. 2007 Spring;8(2):123-6. Rev Cardiovasc Med. 2007. PMID: 17603430 Review. No abstract available.
The safety of rosiglitazone in the treatment of type 2 diabetes.
Singh S, Loke YK. Singh S, et al. Expert Opin Drug Saf. 2008 Sep;7(5):579-85. doi: 10.1517/14740338.7.5.579. Expert Opin Drug Saf. 2008. PMID: 18759710 Review.

See all similar articles

Cited by

The CD36-PPARγ Pathway in Metabolic Disorders.
Maréchal L, Laviolette M, Rodrigue-Way A, Sow B, Brochu M, Caron V, Tremblay A. Maréchal L, et al. Int J Mol Sci. 2018 May 21;19(5):1529. doi: 10.3390/ijms19051529. Int J Mol Sci. 2018. PMID: 29883404 Free PMC article. Review.
Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion.
Zannad F, Stough WG, Lipicky RJ, Tamargo J, Bakris GL, Borer JS, Alonso García Mde L, Hadjadj S, Koenig W, Kupfer S, McCullough PA, Mosenzon O, Pocock S, Scheen AJ, Sourij H, Van der Schueren B, Stahre C, White WB, Calvo G. Zannad F, et al. Eur Heart J Cardiovasc Pharmacother. 2016 Jul;2(3):200-5. doi: 10.1093/ehjcvp/pvw007. Epub 2016 Apr 3. Eur Heart J Cardiovasc Pharmacother. 2016. PMID: 27418973 Free PMC article. Review.
The use of expensive technologies instead of simple, sound and effective lifestyle interventions: a perpetual delusion.
Carlos S, de Irala J, Hanley M, Martínez-González MÁ. Carlos S, et al. J Epidemiol Community Health. 2014 Sep;68(9):897-904. doi: 10.1136/jech-2014-203884. Epub 2014 Jun 24. J Epidemiol Community Health. 2014. PMID: 24962820 Free PMC article. Review.
The determinants of clinical outcome and clinical response to CRT are not the same.
Cleland JG, Ghio S. Cleland JG, et al. Heart Fail Rev. 2012 Nov;17(6):755-66. doi: 10.1007/s10741-011-9268-9. Heart Fail Rev. 2012. PMID: 22081054 Review.
Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes.
Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf BJ, Shen L. Ratner R, et al. Cardiovasc Diabetol. 2011 Mar 16;10:22. doi: 10.1186/1475-2840-10-22. Cardiovasc Diabetol. 2011. PMID: 21410975 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information